We are entirely
We at Brightwater believe that our only ‘metric’ is the QUALY. We are entirely not-for-profit and if we are successful in the development of a new therapeutic approach to Ewing, it may very well be possible that other rare cancers can be treated using the same or similar drugs – one example is malignant nonseminoma, but there may be others.
This is because there is an overlap in both current treatment regimens and gene expression sub-set data that makes it plausible that Valoxydin has wider applications.
Brightwater Research is in the late stages of developing a new drug to stop the spread of the cancer clone cells – using our new drug ‘Valoxydin’ – it does not reduce the primary tumour size whatsoever, but we believe it does shut down the cascade of genetic and biochemical events that make metastasis possible. Metastasis is the main cause of death in Ewing and the reason why so much surgery is employed. Without the cancer metastasizing, life expectancy should dramatically increase. In theory, this should extend life expectancy.
Dr David Garnett
Fellow of the Royal Society of Biology, Member of the International Association for the Study of Lung Cancer, Member of the European Association for Metastasis Research.
David is our chief researcher and the driving force behind Brightwater. Prior to founding the organisation, he was the co-founder and Research Director for Pathway Intermediates Ltd, an industry leading animal nutrition company.
It is David’s deep expertise in cancer cell biology, cell culture, organic synthetic chemistry, transcriptomics and genomic analysis that continues to shape the direction of our ground breaking research.
Edward Youngman MScEcon, BScEcon
Ted is the Chief Operating Officer of Pathway Intermediates Ltd, . His background both as a COO and in prior roles overseeing governance and quality for a major British university, makes him a key member of the trustee board, ensuring that we apply management rigour at all times when running Brightwater.
Sonja Crane MEd, BSc (Hons), FHEA,RGN
With a lengthy career as a senior lecturer in university and hospice settings, Sonja continues to have a keen focus on palliative care and in improving the patient experience. Her engagement and familiarity with these topics, both as a nurse and subsequently in higher education, brings a strong understanding of the ‘human’ element of the impact of cancers to the board.
David Crane MCIPS, MBCS
Dave has a diverse background within IT and Service outsourcing, having worked on many of the world’s largest contracts as Commercial Director and subsequently as the global head of Innovation and emerging technologies for Hewlett Packard.
Dave brings commercial experience and a creative approach to problem solving.